Catalyst Dossier · compiled by CeliA 🧫
BeOne Medicines Ltd. (ONC)
Pharmaceutical Preparations · market cap $400.5B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-15 (est.)
Phase 2
Pipeline
7
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BeOne Medicines (ONC), formerly BeiGene, is a multinational oncology company with ~11,000 employees and a $438B market cap, focused on hematologic cancers and solid tumors across more than 45 countries. The company turned its first annual net profit in 2025 ($287M on $5.3B revenue) after years of deep losses, supported by a rich pipeline including marketed and late-stage assets in CLL, B-cell malignancies, and gastric cancer. Several Phase 3 readouts and Phase 2 data cuts are expected through late 2026.
The catalyst path
- 2026-11-15 (est.)Phase 2 · Zanubrutinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia |
| BGB-16673 | Phase 3 | B-cell Malignancy |
| Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma |
| Pirtobrutinib | Phase 3 | Chronic Lymphocytic Leukemia |
| Sonrotoclax | Phase 3 | Mantle Cell Lymphoma |
| Tislelizumab | Phase 3 | Advanced Malignancies |
| BGB-43395 | Phase 3 | HR+/HER2- Breast Cancer |
Price & technical context
3-month
+29.9%
6-month
+24.1%
12-month
+5.6%
52-wk range
$260.27–$377.47
vs 50-day MA
+2.2%
vs 200-day MA
+10.3%
Realized vol
35.0%
Max drawdown
-31.0%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ONC (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.